Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas-Reference-Cited by-同舟云学术

Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas

Published:2021-09 Issue: Volume: Page:
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Fujino Toshio,Suda Kenichi^ORCID,Sakai Kazuko^ORCID,Murakami Isao,Shimizu Shigeki^ORCID,Ohara Shuta,Koga Takamasa,Hamada Akira,Soh Junichi,Nishio Kazuto,Mitsudomi Tetsuya^ORCID

Funder

Pfizer

AstraZeneca

Bristol-Myers Squibb

Boehringer Ingelheim

Merck Sharp and Dohme

LAM Therapeutics

Eli Lilly and Company

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Capmatinib in MET Exon 14–Mutated or MET-amplified non–small-cell lung cancer;Wolf;N Engl J Med,2020

2. Tepotinib in Non-small-cell lung cancer with MET exon 14 skipping mutations;Paik;N Engl J Med,2020

3. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials;Yang;Lancet Oncol,2015

4. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

5. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors;Frampton;Cancer Discov,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations;Translational Lung Cancer Research;2024-04